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Abstract In the absence of ligands, G-protein coupled receptors 
interconvert between active and inactive conformations. These 
conformations are stabilized by agonists and antagonists, respec- 
tively. Like agonists, G-proteins are thought to preferentially 
associate with receptors in the active conformation and should 
therefore be able to promote their formation in the absence of 
agonist. We show that over-expression of Gq induces constitutive 
activation of compatible muscarinic receptors and that this activ- 
ity is blocked by muscarinic antagonists. Gq also increases the 
potency and efficacy of agonists. These results indicate that reg- 
ulation of G-protein levels has a profound impact on receptor 
control of cellular physiology, even in the absence of agonist 
ligands. 
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1. Introduction 
Muscarinic receptors consist of five genetically defined sub- 
types (ml-m5) that belong to a superfamily of seven transmem- 
brane receptors that couple to G-proteins [14]. The subtypes 
ml ,  m3 and m5 selectively couple the G-protein Gq [5,6]. Many 
receptors have recently been shown to activate G-proteins in 
the absence of agonist [7-11]. Constitutive activity has been 
explained by allosteric models in which receptors exist in equi- 
librium between two conformations, one of which interacts 
with G-proteins [12,13]. Accordingly, agonists are compounds 
that stabilize the active conformation, while antagonists prefer- 
entially interact with the inactive conformation, shifting recep- 
tor equilibrium to enhance or diminish activity, respectively. If 
G-proteins preferentially interact with the active conformation 
of receptors [14], then it follows from these models that increas- 
ing the G-protein concentration should stabilize the active con- 
formation and thus induce constitutive activity. Based upon the 
ability of Gq-selective receptors to induce agonist-dependent 
transformation of NIH 3T3 cells [15], we developed a conven- 
ient assay of receptor activity using the reporter gene fl-galacto- 
sidase (R-SAT, patents pending; [16]; H. Braiiner-Osborne and 
M.R. Brann, submitted). We show that the G-protein Gq in- 
duces constitutive activation of compatible muscarinic receptor 
subtypes. 
*Corresponding author. 
2. Materials and methods 
2.1. Cell culture 
NIH 3T3 cells (ATCC no. CRL 1658) and COS7 cells were incubated 
at 37°C in a humidified atmosphere (5% CO2) in Dulbecco's modified 
Eagles medium supplemented with 4500 mg/l glucose, 4 nM L-glutam- 
ine, 50 U/ml penicillin G, 50 U/ml streptomycin (ABI) and 10% calf 
serum for 3T3 cells or 10% fetal bovine serum for COS7 cells (Gibco). 
2.2. Functional assays 
Receptor-selection and _amplification _technology (R-SAT) assays 
were performed as described previously [16]. Briefly, cells were plated 
1 day before transfection using 1 x 106 cells in 10 ml of medium per 10 
cm plate. Cells were transfected by calcium precipitation as described 
[30] using 1-3/lg each of the human rnuscarinic receptor subtypes (ml, 
m2, m3, m5), pSV-fl-galactosidase (Promega, Madison, WI), G~q (gen- 
erous gift from B. Conklin) or control vector, and 20/zg of salmon 
sperm DNA (Sigma, St. Louis, MO). One day after transfection media 
were changed, and after 2 days cells were trypsinized and aliquoted into 
the wells of a 96-well plate (100/.t/well). One 10 cm plate yields enough 
cells for 96 wells. Ligands were combined with the cells to a final volume 
of 200/,tl/well. After 5 days in culture fl-galactosidase l vels were meas- 
ured as described [31]. Media were aspirated from the wells and the cells 
rinsed with phosphate buffered saline (PBS). 200/zl of PBS containing 
3.5 mM O-nitrophenyl-fl-D-galactopyranoside an  0.5% nonidet P-40 
(both Sigma, St. Louis, MO) were added to each well and the 96-well 
plate was incubated at room temperature. After 16 h the plates were 
read at 405 nm on a plate-reader (Bio-Tek EL 310 or Molecular De- 
vices). Data from R-SAT assays were fitted to the equation: 
R = D + (A - D)/(I + (x/c)) 
where A = minimum response, D = maximum response and c = ECs0 
(R = response, x = concentration f ligand). Curves were generated by 
least-squares fits using the program KaleidaGraph (Abelbeck Soft- 
ware). 
3. Results 
3.1. Gaq induces constitutive activation of the m3 muscarinic 
receptor 
As shown in Fig. 1A when NIH 3T3 cells transfected with 
the m3 muscarinic receptor and the fl-galactosidase g ne were 
cultured in the presence of the indicated concentrations of the 
muscarinic agonist carbachol, there was a dose-dependent i -
crease in ]3-galactosidase activity. When we co-expressed the 
subunit of G=q [17-19] there was a dramatic increase in basal 
activity, representing approximately 25% of the total response 
(Fig. 1A). Besides inducing constitutive activity, G~q also 
caused a 36-fold leftward shift of the carbachol dose-response 
curve (Fig. 1A, Table 1). The G~q induced activity was reversed 
in a dose-dependent manner by the potent muscarinic antago- 
nist atropine, indicating it is actually a negative antagonist (Fig. 
IA). The compound McN-434 is a weak partial agonist, with 
only a third of the efficacy of carbachol (Fig. 1 B, Table 1). G~q 
co-expression i creased the efficacy of McN-434 to 70% of 
carbachol, and also increased its potency, although to a lesser 
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Fig. 1. Constitutive activation of the m3 muscarinic receptor by Gq. m3 and fl-galactosidase w re transfected into NIH 3T3 cells either with or without 
G~q and cultured in the presence of the indicated concentrations ofeither (A) carbachol (A = m3 + Gq, • = m3); atropine (* = m3 + Gq, • -- m3) 
or (B) McN-434 (A = m3 + Gq, • = rn3); pirenzepine (A = m3 + Gq, • = m3). 
extent han for carbachol (Fig. 1B, Table 1). We also tested the 
muscarinic antagonist pirenzepine and found that, like 
atropine, it is actually a negative antagonist, reversing the con- 
stitutive activity induced by G~q (Fig. 1B). In contrast o the 
results for agonists, G~q over-expression did not significantly 
alter the ECs0 for either antagonist compared with their K1 
values (Table 1). 
3.2. Constitutive activation of  receptors by G-proteins is specific 
to compatible pairs 
Similar effects of G~q were observed on ml and m5, but not 
the m2 muscarinic receptor subtypes (not shown). Unlike G~q, 
the G-protein G~I 2 [20], which also mediates proliferative re- 
sponses in NIH 3T3 cells [21-23], had no effect on muscarinic 
receptor activity. Expression of either G~q or G~12 alone caused 
slight cellular esponses which were neither atropine- nor car- 
bachol-sensitive. We recently isolated constitutively activated 
m5 muscarinic receptors from a library of receptors with muta- 
tions randomly incorporated into the sixth transmembrane do- 
main (T.A. Spalding et al., submitted). The phenotypes of these 
mutant receptors were almost indistinguishable from those in- 
duced by Geq in the present study. The mutant receptors had 
constitutive activity that was suppressed by the antagonists 
atropine and pirenzepine, the potency of the antagonists was 
unchanged, and the potencies of agonists were increased in 
proportion to their efficacy (i.e. carbachol exhibited a greater 
shift in potency than McN-434). To exclude the possibility that 
the constitutive activities were due to trace amounts of the 
endogenous agonist acetylcholine, we repeated our experiments 
in synthetic media and obtained similar results (not shown). 
Furthermore, acetylcholine is totally ineffective in our cellular 
assay, presumably due to cholinesterases in the serum, as is its 
breakdown product choline (T.A. Spalding et al., submitted). 
4.  D iscuss ion  
The model shown below both predicts and explains all of our 
observations. 
R ~ R* + G ~ R*G ---r RESPONSE 
In this model receptors exist in equilibrium between inactive 
(R) and active (R*) conformations. Agonists and G-proteins 
have higher affinity for R* while antagonists preferentially bind 
R. When compatible receptor/G-protein combinations are co- 
expressed we observe constitutive activity. Agonists acquire 
increased potency and efficacy whereas the potencies of antag- 
onists are unaffected. All these results can be explained if G- 
proteins increase the proportion of R* independently of ag- 
onist, assuming the receptor exists primarily as R in the absence 
of added agonists. 
These observations have implications for the regulation of 
cellular physiology by receptors. Basal tone may be an impor- 
tant component of muscarinic (and other receptor) physiology. 
In fact, it has been shown that treatment of atrial cell mem- 
branes with muscarinic antagonists blocks spontaneous K + 
channel opening and G-protein activity [24,25]. Our observa- 
tions imply that the control of G-protein expression may pro- 
foundly contribute to these phenomena. It is known that the 
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Table 1 
Effects of Gq on m3 muscarinic receptor pharmacology 
ECs0 (nM) Ratio 
m3 m3 + Gq 
Carbachol 790 + 190 22 _+ 6 36 
(100) (84) 
McN-434 3300 + 120 400 _+ 90 8.2 
(32) (70) 
Atropine n.r. 1.3 -I_-_ 0.3 1.0" 
(-22) 
Pirenzepine n.r. 100 _+ 80 2.5* 
(-18) 
The maximum responses (above basal) are shown in parentheses and 
were calculated as percent maximum response (above basal) of m3 to 
carbachol. A negative value indicates uppression of basal activity and 
was also normalized to the maximum response of m3 to carbachol. 
Ratios were calculated as ECso,m3/ECso.rn3 + Gq" *For comparing the ECs0 
values of antagonists we used Ki values determined for antagonism of 
carbachol responses at m3 (Jorgensen and Brann, manuscript submit- 
ted). Values are reported as the mean + S.E.M. and are taken from an 
experiment done in duplicate which is representative of four separate 
experiments. 
subcellular locations and levels are tightly regulated by physio- 
logical stimuli [26-28], and regulation of G~q levels by compat- 
ible muscarinic receptors has been documented [29]. Thus con- 
stitutive receptor activity induced by G-proteins may be an 
important component of normal cellular physiology. 
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